Universal screening for hemoglobinopathies using high-performance liquid chromatography: clinical results of 2.2 million screens.
In screening for hemoglobinopathies, high-performance liquid chromatography (HPLC) achieves excellent sensitivity and specificity, while adding the very important quantitative element to the analysis. Due to the development of a rapid, automated HPLC system, California began screening 600,000 births per year in 1990 using this method. Based on confirmatory testing for 97% of the initial positive results resulting from 2.2 million screens, HPLC has proven to be clinically accurate. In conjunction with the availability of quantitative data, HPLC provides a complete screening system, eliminating the need for a second screening test, and accurately discriminating beta thalassemia compound conditions. The large degree of ethnic diversity and high birth rate in California have produced detailed and reliable birth prevalence rates for most conditions and ethnicities.
Lorey
F
F
Genetic Disease Branch, California Department of Health Services, Berkeley.
Cunningham
G
G
Shafer
F
F
Lubin
B
B
Vichinsky
E
E
D001769:Blood; D002140:California / Q000453:epidemiology; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005006:Ethnicity; D006453:Hemoglobinopathies / Q000453:epidemiology*; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening; D015995:Prevalence; D017086:beta-Thalassemia / Q000453:epidemiology*